Artiva is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers. The company's lead product, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy designed to work with monoclonal antibodies to achieve B-cell depletion, with applications in rheumatoid arthritis, lupus, and other B-cell-driven autoimmune conditions as well as B-cell lymphomas. Artiva's competitive advantages center on scalability (derived from cord blood rather than patient-specific manufacturing), superior safety profile, lower estimated manufacturing costs, and first-mover advantage in allogeneic off-the-shelf NK therapies for autoimmune indications; the company operates a proprietary, highly scalable manufacturing process and generates potential revenue through product sales and partnerships, though it remains pre-revenue pending regulatory approval and commercialization.